July 5: The Week in Cancer News
Neuropathy may be prevented with an exercise program, and prostate cancer screening standards may not be appropriate for transgender women taking estrogen.
Progress Against Cancer
Neuropathy may be prevented with an exercise program, and prostate cancer screening standards may not be appropriate for transgender women taking estrogen.
Immune checkpoint inhibitors are effective against non-small cell lung cancer in some patients. Researchers are investigating who benefits from the drugs and when they should be administered for maximum impact.
With the FDA’s approval of the first tumor‑infiltrating lymphocyte (TIL) therapy to treat advanced melanoma, researchers seek to expand this type of cellular therapy to other solid tumors.
The drug showed promise in treating small cell lung cancer that had progressed during or after chemotherapy.
Acupuncture helps manage side effects of endocrine therapy, and adding chemotherapy before surgery delays progression in pancreatic cancer.
Patients given waivers to participate in A trial had outcomes the same or slightly better than people who met the standard requirements; findings support broader and more inclusive trial designs. Cancer patients sometimes find...
The FDA approved the immunotherapy epcoritamab-bysp for certain patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to epcoritamab-bysp (Epkinly) for the treatment of adult patients with follicular...
The FDA issued its first approval for the use of A KRAS G12C inhibitor in a tumor type other than lung. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to adagrasib...
Risk for cancer and cardiovascular disease linked to air pollution, and three cancer drugs could face generic competition by 2028.
Transgender and gender nonconforming people are most likely to have continuing conditions, regardless of age, race and ethnicity, smoking history, and socioeconomic status, according to A study. Of people who have survived cancer, those...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now